New Advances in the Treatment of Chronic Myelogenous Leukemia

Download Podcast

Listen to MP3

Podcast Evaluation

A presentation from the NCCN 13^th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida.

Presenter

Susan O’Brien, MD
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Program Goal

The goal of this program is to provide participants with increased knowledge regarding the innovative therapies and treatment methods used for the management of patients with chronic myelogenous leukemia (CML).

Educational Objectives

Following this activity, participants should be able to:

• Identify recent developments in treatment options for chronic myelogenous leukemia CML
• Explain how these developments can help patients with CML
• Describe the development of imatinib resistance and management strategies for patients who develop resistance

Intended Audience

This educational activity is designed to meet the educational needs of physicians, nurses, and other clinical professionals who manage patients with cancer.

Activity Instructions

Continuing education credit will be awarded to participants who view the presentation, pass the post-test with a score of 80% or higher, and complete the evaluation.  Participants should review the learning objectives and faculty disclosure statement prior to viewing and listening to a presentation in its entirety.  You must be connected to the Internet in order to review and complete the post-test and the evaluation form.  A statement of credit will be electronically generated once you pass the post-test and complete the evaluation form.  To receive credit, this activity must be completed no later than May 23, 2009.  There is no fee for participating in this activity.

Download Podcast

Listen to MP3

Podcast Evaluation

Accreditation Information

Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NCCN designates this educational activity for a maximum of 0.75 AMA PRA Category 1
Credit(s)™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This activity is approved for 0.8 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Release date:  May 23, 2008
Expiration date:  May 23, 2009

Commercial Support

Supported by an unrestricted educational grant from Novartis Oncology